FLT4 and lung adenocarcinoma: Similarly, in a study of lung adenocarcinoma mouse models (14), anlotinib inhibited the growth and migration of human lymphatic endothelial cells and lymphangiogenesis in vitro and in vivo, probably through the inactivation of VEGFR-3 phosphorylation (28).